Insulin icodec: A novel once-weekly treatment for diabetes.
diabetes
diabetes mellitus
diabetes mellitus, type 1
diabetes mellitus, type 2
insulin
insulin, long‐acting
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
revised:
21
06
2024
received:
12
06
2023
accepted:
09
07
2024
medline:
24
7
2024
pubmed:
24
7
2024
entrez:
24
7
2024
Statut:
aheadofprint
Résumé
To summarize the results of clinical studies of insulin icodec, an investigational insulin analog designed for once-weekly administration, in adults with type 1 and type 2 diabetes. Thirteen published articles describing clinical studies of insulin icodec were identified in PubMed, and data pertinent to key study outcomes were selected for inclusion in this review. In insulin-naïve and insulin-treated individuals, icodec demonstrated efficacy in glycaemic control superior or noninferior to that of insulins glargine U100, glargine U300 and degludec. Icodec exhibited a safety profile comparable to marketed insulins, with the exception of hypoglycaemic event rates. As a once-weekly alternative to daily basal insulin, icodec is expected to improve patient adherence and satisfaction, reducing the required number of injections per year from 365 to 52 and providing a dosing option potentially attractive to a wide range of insulin users. However, clinical data suggest a notable risk of hypoglycaemia with weekly icodec administration, especially in individuals with type 1 diabetes.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15414Subventions
Organisme : No funding was received.
Informations de copyright
© 2024 Diabetes UK.
Références
Kjeldsen TB, Hubálek F, Hjørringgaard CU, et al. Molecular engineering of insulin ICODEC, the first acylated insulin analog for once‐weekly administration in humans. J Med Chem. 2021;64(13):8942‐8950.
Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once‐weekly dosing. BMJ Open Diabetes Res Care. 2021;9(1):1‐10.
Pieber T, Asong M, Fluhr G, et al. Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes. Diabetes Obes Metab. 2023;25:3716‐3723.
Hövelmann U, Engberg S, Heise T, et al. Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes. Diabetes Obes Metab. 2024;26:1941‐1949.
Rosenstock J, Bajaj HS, Janež A, et al. One‐weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383(22):2107‐2116.
Lingvay I, Buse JB, Franek E, et al. A randomized, open‐label comparison of once‐weekly insulin Icodec titration strategies versus once‐daily insulin glargine U100. Diabetes Care. 2021;44(7):1595‐1603.
Bajaj HS, Bergenstal RM, Christoffersen A, et al. Switching to once‐weekly insulin Icodec versus once‐daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586‐1594.
Rosenstock J, Bain S, Gowda A, et al. Weekly Icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389(4):297‐308.
Philis‐Tsimikas A, Asong M, Franek E, et al. Switching to once‐weekly insulin icodec versus once‐daily insulin degludec in individuals with basal insulin‐treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat‐to‐target trial. Lancet Diabetes Endocrinol. 2023;11(5):1‐12.
Lingvay I, Asong M, Desouza C, et al. Once‐weekly insulin Icodec vs once‐daily insulin Degludec in adults with insulin‐naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330(3):228‐237.
Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once‐weekly insulin icodec versus once‐daily insulin glargine U100 in individuals with basal‐bolus insulin‐ treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open‐label, multicentre, treat‐to‐target, non‐inferiority trial. Lancet. 2023;401(10389):1‐12.
Bajaj HS, Aberle J, Davies M, et al. Once‐weekly insulin Icodec with dosing guide app versus once‐daily basal insulin analogues in insulin‐naive type 2 diabetes (ONWARDS 5). Ann Intern Med. 2023;176:1476‐1485.
Russell‐Jones D, Babazono T, Callieteau R, et al. Once‐weekly insulin icodec versus once‐daily insulin degludec as part of a basal‐bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open‐label, treat‐to‐target trial. Lancet. 2023;402(10413):1636‐1647.
Saisho Y. Use of diabetes treatment satisfaction questionnaire in diabetes care: importance of patient‐reported outcomes. J Environ Res Public Health. 2018;15(5):947.
Brod M, Christensen T, Hammer M, Busk AK, Bushnell DM. Examining the ability to detect change using the trim‐diabetes and trim‐diabetes device measures. Qual Life Res. 2011;20(9):1513‐1518.
Bajaj HS, Ásbjörnsdóttir B, Carstensen L, et al. Continuous glucose monitoring–based metrics and hypoglycemia duration in insulin‐experienced individuals with long‐standing type 2 diabetes switched from a daily basal insulin to once‐weekly insulin Icodec: post hoc analysis of ONWARDS 2 and ONWARDS 4. Diabetes Care. 2024;47(4):729‐738.
European Medicines Agency. Awiqli: EPAR—Medicine Overview. 2022. Accessed June 18, 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/awiqli#overview
Swissmedic. Awiqli® FlexTouch®, Injection Solution in Prefilled Pen (Insulin icodecum). Accessed Jun 10 2024. https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/authorisations/new‐medicines/awiqli‐flextouch‐injlsg‐fertigpen‐insulinum‐icodecum.html
Canadian Agency for Drugs and Technologies in Health. Insulin Icodec. Accessed June 10, 2024. https://www.cadth.ca/insulin‐icodec
United States Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting. 2024. Accessed Jun 10, 2024. https://www.youtube.com/watch?v=jeJQNP1Ug2I